TNFRSF11B and osteoporosis: Partial non-steroidal GR agonists AZD7495 and AZD9567 developed by AstraZeneca retained full capability to induce GR TR (assessed by inhibition of LPS induced TNFα release in human blood cells), but did not activate specific genes involved in osteoporosis (induction of osteoprotegerin, OPG, in human osteoblasts) and glucose metabolism (assessed in human hepatocytes by activation of tyrosine aminotransferase, TAT).